NASDAQ:MNKD - MannKind Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$1.33 -0.05 (-3.62 %)
(As of 01/17/2019 01:48 AM ET)
Previous Close$1.38
Today's Range$1.31 - $1.40
52-Week Range$0.94 - $4.05
Volume1.63 million shs
Average Volume2.48 million shs
Market Capitalization$217.05 million
P/E Ratio-1.15
Dividend YieldN/A
Beta2.43
MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for diabetes and pulmonary arterial hypertension patients. It offers Afrezza, a dry powder formulation of human insulin that controls high blood sugar in adults with type 1 and type 2 diabetes in the United States. The company has a licensing and collaboration agreement with United Therapeutics Corporation for the development and commercialization of a dry powder formulation of treprostinil used for the treatment of pulmonary arterial hypertension. MannKind Corporation was founded in 1991 and is headquartered in Westlake Village, California.

Receive MNKD News and Ratings via Email

Sign-up to receive the latest news and ratings for MNKD and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:MNKD
CUSIP56400P20
Phone818-661-5000

Debt

Current Ratio0.33
Quick Ratio0.28

Price-To-Earnings

Sales & Book Value

Annual Sales$11.74 million
Price / Sales18.08
Price / Cash FlowN/A
Book Value($1.81) per share
Price / Book-0.73

Profitability

Net Income$-117,330,000.00
Net Margins-672.57%
Return on Assets-171.99%

Miscellaneous

Employees250
Market Cap$217.05 million
OptionableOptionable

MannKind (NASDAQ:MNKD) Frequently Asked Questions

What is MannKind's stock symbol?

MannKind trades on the NASDAQ under the ticker symbol "MNKD."

How were MannKind's earnings last quarter?

MannKind Co. (NASDAQ:MNKD) posted its quarterly earnings results on Thursday, November, 1st. The biopharmaceutical company reported ($0.16) earnings per share for the quarter, topping the Zacks' consensus estimate of ($0.18) by $0.02. The biopharmaceutical company had revenue of $4.47 million for the quarter, compared to analysts' expectations of $5.28 million. View MannKind's Earnings History.

When is MannKind's next earnings date?

MannKind is scheduled to release their next quarterly earnings announcement on Tuesday, February 26th 2019. View Earnings Estimates for MannKind.

What price target have analysts set for MNKD?

2 analysts have issued 12 month price targets for MannKind's shares. Their predictions range from $1.00 to $4.00. On average, they expect MannKind's stock price to reach $2.59 in the next year. This suggests a possible upside of 94.7% from the stock's current price. View Analyst Price Targets for MannKind.

What is the consensus analysts' recommendation for MannKind?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for MannKind in the last year. There are currently 1 sell rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for MannKind.

What are Wall Street analysts saying about MannKind stock?

Here are some recent quotes from research analysts about MannKind stock:
  • 1. According to Zacks Investment Research, "Mannkind Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutic products for diseases such as diabetes, cancer, inflammatory and autoimmune diseases. The Company's lead product, the Technosphere Insulin System, consists of the Company's dry-powder Technosphere formulation of insulin and the Company's MedTone inhaler through which the powder is inhaled into the deep lung. " (7/11/2018)
  • 2. HC Wainwright analysts commented, "Exchange NASDAQ Value (M) $324.5 Market Cap (M) $238 Shares Outstanding (M) 133.1 3 Interest (M) 32.53 Cash (M) $53.5 Total Debt (M) $140.0 Year – (0.15) FY (1.13) (0.83) (0.65) FY P/E NM NM NM Year – 14.7 FY 11.7 20.8 45.4 8 6 4 2 0 0 Vol. (mil) the science to drive Afrezza awareness and adoption." (5/10/2018)

Has MannKind been receiving favorable news coverage?

Media stories about MNKD stock have been trending positive this week, according to InfoTrie Sentiment Analysis. InfoTrie ranks the sentiment of press coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. MannKind earned a media sentiment score of 2.3 on InfoTrie's scale. They also assigned press coverage about the biopharmaceutical company a news buzz of 5.0 out of 10, indicating that recent press coverage is somewhat likely to have an effect on the stock's share price in the near term.

Are investors shorting MannKind?

MannKind saw a decline in short interest during the month of December. As of December 31st, there was short interest totalling 39,444,951 shares, a decline of 4.2% from the December 14th total of 41,172,380 shares. Based on an average daily trading volume, of 4,153,281 shares, the short-interest ratio is presently 9.5 days. Currently, 22.9% of the company's shares are short sold. View MannKind's Current Options Chain.

Who are some of MannKind's key competitors?

Who are MannKind's key executives?

MannKind's management team includes the folowing people:
  • Dr. Michael E. Castagna, CEO & Director (Age 41)
  • Mr. Steven B. Binder, Chief Financial Officer (Age 55)
  • Mr. Joseph Kocinsky, Chief Technology Officer (Age 54)
  • Ms. Rosabel Realica Alinaya, Sr. VP of Investor Relations & Treasury (Age 57)
  • Dr. David B. Thomson, Corp. VP, Gen. Counsel & Sec. (Age 51)

Who are MannKind's major shareholders?

MannKind's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Virtu Financial LLC (0.03%). Company insiders that own MannKind stock include Kent Kresa, Michael Castagna, Raymond W Urbanski, Rosabel Realica Alinaya, Steven B Binder and Stuart A Tross. View Institutional Ownership Trends for MannKind.

Which institutional investors are buying MannKind stock?

MNKD stock was acquired by a variety of institutional investors in the last quarter, including Virtu Financial LLC. Company insiders that have bought MannKind stock in the last two years include Kent Kresa, Michael Castagna, Rosabel Realica Alinaya, Steven B Binder and Stuart A Tross. View Insider Buying and Selling for MannKind.

How do I buy shares of MannKind?

Shares of MNKD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is MannKind's stock price today?

One share of MNKD stock can currently be purchased for approximately $1.33.

How big of a company is MannKind?

MannKind has a market capitalization of $217.05 million and generates $11.74 million in revenue each year. The biopharmaceutical company earns $-117,330,000.00 in net income (profit) each year or ($1.16) on an earnings per share basis. MannKind employs 250 workers across the globe.

What is MannKind's official website?

The official website for MannKind is http://www.mannkindcorp.com.

How can I contact MannKind?

MannKind's mailing address is 30930 RUSSELL RANCH ROAD SUITE 301, WESTLAKE VILLAGE CA, 91362. The biopharmaceutical company can be reached via phone at 818-661-5000 or via email at [email protected]


MarketBeat Community Rating for MannKind (NASDAQ MNKD)

Community Ranking:  2.2 out of 5 (star star)
Outperform Votes:  454 (Vote Outperform)
Underperform Votes:  590 (Vote Underperform)
Total Votes:  1,044
MarketBeat's community ratings are surveys of what our community members think about MannKind and other stocks. Vote "Outperform" if you believe MNKD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MNKD will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/17/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel